Aragona Cesare, Bezerra Espinola Maria Salomè, Bilotta Gabriele, Porcaro Giuseppina, Calcagno Marco
Systems Biology Group Lab, 00161 Rome, Italy.
Alma Res Fertility Center, 00198 Rome, Italy.
J Clin Med. 2023 Mar 10;12(6):2171. doi: 10.3390/jcm12062171.
The persistence of the HPV infection is a risk factor in the integration of viral DNA in the host genome, leading to transforming events. The lack of therapies for HPV-persistent infections determine an unmet medical need.
We enrolled forty patients with persistent HPV infections and cervical lesions and divided them into two groups. The women in the treated group received 200 mg epigallocatechin gallate (EGCG), 400 µg folic acid (FA), 1 mg vitamin B12, and 50 mg hyaluronic acid (HA) for 12 weeks. The control group received no treatment.
40 patients completed the study. Fifteen out of 20 women in the control group still had an LSIL at the end of the study. One woman had a decrease in the DNA load, while six had no change and eight had an increase in DNA content. In the treatment group, 17 out of 20 women achieved a full viral clearance. These women showed no cytological or histological evidence of lesions following the treatment.
Our data highlight the possible effect of such combination on LSIL. Therefore, the evidence reported here supports the potential to carry out further randomized placebo-controlled studies with an adequate number of patients to verify our results.
人乳头瘤病毒（HPV）感染的持续存在是病毒DNA整合到宿主基因组中导致转化事件的一个风险因素。缺乏针对HPV持续感染的治疗方法表明存在未满足的医疗需求。
我们招募了40例HPV持续感染且伴有宫颈病变的患者，并将她们分为两组。治疗组的女性接受200毫克表没食子儿茶素没食子酸酯（EGCG）、400微克叶酸（FA）、1毫克维生素B12和50毫克透明质酸（HA），持续12周。对照组未接受治疗。
40例患者完成了研究。对照组的20名女性中有15名在研究结束时仍有低度鳞状上皮内病变（LSIL）。1名女性的DNA载量下降，6名无变化，8名DNA含量增加。在治疗组中，20名女性中有17名实现了病毒完全清除。这些女性在治疗后未显示出病变的细胞学或组织学证据。
我们的数据突出了这种联合用药对LSIL可能产生的影响。因此，此处报告的证据支持开展进一步的随机安慰剂对照研究的可能性，研究要有足够数量的患者以验证我们的结果。
